We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
EXTENCILLINE benzathine benzylpenicillin 1.2 Million IU, powder and solvent for suspension for IM injection (France)
Section 19A approved medicine
EXTENCILLINE benzathine benzylpenicillin 1.2 Million IU, powder and solvent for suspension for IM injection (France)
Section 19A approval holder
ORSPEC Pharma Pty Ltd ABN 15 634 980 417
Phone
02 4339 4239
Approved until
Status
Current
Medicines in short supply/unavailable
BICILLIN L-A benzathine benzylpenicillin tetrahydrate 1,200,000 Units / 2.3 mL suspension for injection pre-filled syringe with needle - ARTG 147169
Indication(s)
Intramuscular benzathine benzylpenicillin is indicated in the treatment of infections due to penicillin-sensitive microorganisms that are susceptible to the low and very prolonged serum levels common to this particular dosage form.
Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response.
The following infections will usually respond to adequate dosage of intramuscular benzathine benzylpenicillin:
Streptococcal infections (Group A - without bacteraemia).
Mild-to- moderate infections of the upper respiratory tract (e.g., pharyngitis).
Venereal infections - Syphilis, yaws, bejel and pinta.
Medical conditions in which benzathine benzylpenicillin therapy is indicated as prophylaxis:
Rheumatic fever and/or chorea - Prophylaxis with benzathine benzylpenicillin has proven effective in preventing recurrence of these conditions. It has also been used as followup prophylactic therapy for rheumatic heart disease and acute glomerulonephritis.
Images
